Strategies to enhance the therapeutic efficacy of antidepressants: targeting residual symptoms

References

• Diagnostic and Statistical Manual of Mental Disorders – Text Revision. American Psychiatric Association, DC, USA (2000).
   Google Scholar
• Murray CJ, Lopez AD. Evidence-based health policy – lessons from the Global Burden of Disease Study. Science274(5288), 740–743 (1996).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Akiskal HS, Ames M et al. Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers. Am. J. Psychiatry163(9), 1561–1568 (2006).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Kraemer HC, Sackeim HA et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology31(9), 1841–1853 (2006).
   PubMed Web of Science ®Google Scholar
• Paykel ES, Ramana R, Cooper Z et al. Residual symptoms after partial remission: an important outcome in depression. Psychol. Med.25(6), 1171–1180 (1995).
   PubMed Web of Science ®Google Scholar
• Olfson M, Marcus SC, Druss B et al. National trends in the outpatient treatment of depression. JAMA287(2), 203–209 (2002).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry163(1), 28–40 (2006).
   PubMed Web of Science ®Google Scholar
• Keller MB, Gelenberg AJ, Hirschfeld RM et al. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J. Clin. Psychiatry59(11), 598–607 (1998).
   PubMed Web of Science ®Google Scholar
• Keller MB, McCullough JP, Klein DN et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N. Engl. J. Med.342(20), 1462–1470 (2000).
   PubMed Web of Science ®Google Scholar
• Hennings JM, Owashi T, Binder EB et al. Clinical characteristics and treatment outcome in a representative sample of depressed inpatients – findings from the Munich Antidepressant Response Signature (MARS) project. J. Psychiatr. Res.43(3), 215–229 (2008).
   PubMedGoogle Scholar
• Judd LL, Akiskal HS, Zeller PJ et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch. Gen. Psychiatry57(4), 375–380 (2000).
   PubMed Web of Science ®Google Scholar
• Judd LL, Paulus MJ, Schettler PJ et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am. J. Psychiatry157(9), 1501–1504 (2000).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Fava M, Wisniewski SR et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control. Clin. Trials25(1), 119–142 (2004).
   PubMedGoogle Scholar
• Fava M, Rush AJ. Current status of augmentation and combination treatments for major depressive disorder: a literature review and a proposal for a novel approach to improve practice. Psychother. Psychosom.75(3), 139–153 (2006).
   PubMed Web of Science ®Google Scholar
• National Institute of Mental Health Strategic Plan. US Department of Health and Human Services, National Institutes of Health, NIH Publication No. 08–6368, 22–23 (2008).
   Google Scholar
• Altshuler LL, Bauer M, Frye MA et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am. J. Psychiatry158(10), 1617–1622 (2001).
   PubMed Web of Science ®Google Scholar
• Bauer M, Bschor T, Kunz D et al. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am. J. Psychiatry157(9), 1429–1435 (2000).
   PubMed Web of Science ®Google Scholar
• Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J. Clin. Psychiatry68(6), 935–940 (2007).
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Fava M, Trivedi MH et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am. J. Psychiatry163(9), 1519–1530 (2006).
   PubMed Web of Science ®Google Scholar
• Ros S, Aguera L, de la Gandara J, Rojo JE, de Pedro JM. Potentiation strategies for treatment-resistant depression. Acta Psychiatr. Scand. Suppl.36(428), 14–24, (2005).
   Google Scholar
• Fava M, Thase ME, DeBattista C et al. Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepiness. Ann. Clin. Psychiatry19(3), 153–159 (2007).
   PubMedGoogle Scholar
• Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J. Clin. Psychiatry60(Suppl. 22), 29–34 (1999).
   PubMed Web of Science ®Google Scholar
• Fava M, Alpert JE, Carmin CN et al. Clinical correlates and symptom patterns of anxious depression among patients with major depressive disorder in STAR*D. Psychol. Med.34(7), 1299–1308 (2004).
   PubMed Web of Science ®Google Scholar
• Farabaugh A, Fava M, Mischoulon D et al. Relationships between major depressive disorder and comorbid anxiety and personality disorders. Compr. Psychiatry46(4), 266–271 (2005).
   PubMedGoogle Scholar
• Silverstone PH, von Studnitz E. Defining anxious depression: going beyond comorbidity. Can. J. Psychiatry48(10), 675–680 (2003).
   PubMed Web of Science ®Google Scholar
• Kessler RC, Nelson CB, McGonagle KA et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br. J. Psychiatry Suppl. (30), 17–30 (1996).
   PubMedGoogle Scholar
• Fava M, Rush AJ, Alpert JE et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am. J. Psychiatry165(3), 342–351 (2008).
   PubMed Web of Science ®Google Scholar
• Dunner DL. Management of anxiety disorders: the added challenge of comorbidity. Depress. Anxiety13(2), 57–71 (2001).
   PubMed Web of Science ®Google Scholar
• Greer TL, Trivedi MH. Comorbid depression and anxiety: characteristics, functional consequences, and treatment considerations. Univ. Virg. Sch. Med. Rep. Psychiatr. Disord.2(2), 1–8 (2005).
   Google Scholar
• Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress. Anxiety4(4), 160–168 (1996).
   PubMedGoogle Scholar
• Harter MC, Conway KP, Merikangas KR. Associations between anxiety disorders and physical illness. Eur. Arch. Psychiatry Clin. Neurosci.253(6), 313–320 (2003).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen T, Hughes ME et al. Anxiety and somatic symptoms as predictors of treatment-related adverse events in major depressive disorder. Psychiatry Res.126(3), 287–290 (2004).
   PubMed Web of Science ®Google Scholar
• Lydiard RB, Brawman-Mintzer O. Anxious depression. J. Clin. Psychiatry59(Suppl. 18), 10–17 (1998).
   PubMed Web of Science ®Google Scholar
• Dunlop BW, Davis PG. Combination treatment with benzodiazepines and SSRIs for comorbid anxiety and depression: a review. Prim. Care Companion J. Clin. Psychiatry10(3), 222–228 (2008).
   PubMedGoogle Scholar
• Davidson JR, Meoni P, Haudiquet V, Cantillon M, Hackett D. Achieving remission with venlafaxine and fluoxetine in major depression: its relationship to anxiety symptoms. Depress. Anxiety16(1), 4–13 (2002).
   PubMed Web of Science ®Google Scholar
• Dunner DL, Goldstein DJ, Mallinckrodt C, Lu Y, Detke MJ. Duloxetine in treatment of anxiety symptoms associated with depression. Depress. Anxiety18(2), 53–61 (2003).
   PubMed Web of Science ®Google Scholar
• Buysse DJ, Angst J, Gamma A et al. Prevalence, course, and comorbidity of insomnia and depression in young adults. Sleep31(4), 473–480 (2008).
   PubMed Web of Science ®Google Scholar
• Thase ME. Antidepressant treatment of the depressed patient with insomnia. J. Clin. Psychiatry60(Suppl. 17), 28–31; discussion 46–48 (1999).
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Keefe BR, Leslie VC et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J. Clin. Psychiatry60(4), 221–225 (1999).
   PubMed Web of Science ®Google Scholar
• Buckner JD, Bernert RA, Cromer KR, Joiner TE, Schmidt NB. Social anxiety and insomnia: the mediating role of depressive symptoms. Depress. Anxiety25(2), 124–130 (2008).
   PubMed Web of Science ®Google Scholar
• Fava M. Daytime sleepiness and insomnia as correlates of depression. J. Clin. Psychiatry65(Suppl. 16), 27–32 (2004).
   PubMed Web of Science ®Google Scholar
• Asnis GM, Chakraburtty A, DuBoff EA et al. Zolpidem for persistent insomnia in SSRI-treated depressed patients. J. Clin. Psychiatry60(10), 668–676 (1999).
   PubMed Web of Science ®Google Scholar
• Fava M, McCall WV, Krystal A et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol. Psychiatry59(11), 1052–1060 (2006).
   PubMed Web of Science ®Google Scholar
• Becker PM. Treatment of sleep dysfunction and psychiatric disorders. Curr. Treat. Options Neurol.8(5), 367–375 (2006).
   PubMedGoogle Scholar
• Kupfer DJ. Pathophysiology and management of insomnia during depression. Ann. Clin. Psychiatry11(4), 267–276 (1999).
   PubMedGoogle Scholar
• Henningsen P, Zimmermann T, Sattel H. Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review. Psychosom. Med.65(4), 528–533 (2003).
   PubMed Web of Science ®Google Scholar
• Deldin PJ, Phillips LK, Thomas RJ. A preliminary study of sleep-disordered breathing in major depressive disorder. Sleep Med.7(2), 131–139 (2006).
   PubMedGoogle Scholar
• O’Hara R, Schroder C. Unraveling the relationship of obstructive sleep-disordered breathing to major depressive disorder. Sleep Med.7(2), 101–103 (2006).
   PubMedGoogle Scholar
• Baldwin DS, Papakostas GI. Symptoms of fatigue and sleepiness in major depressive disorder. J. Clin. Psychiatry67(Suppl. 6), 9–15 (2006).
   PubMed Web of Science ®Google Scholar
• Preti A. Tomoxetine (Eli Lilly & Co). Curr. Opin. Investig. Drugs3(2), 272–277 (2002).
   PubMedGoogle Scholar
• Papakostas GI, Petersen TJ, Burns AM, Fava M. Adjunctive atomoxetine for residual fatigue in major depressive disorder. J. Psychiatr. Res.40(4), 370–373 (2006).
   PubMed Web of Science ®Google Scholar
• Michelson D, Adler LA, Amsterdam JD et al. Addition of atomoxetine for depression incompletely responsive to sertraline: a randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry68(4), 582–587 (2007).
   PubMed Web of Science ®Google Scholar
• Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J. Clin. Psychiatry66(1), 85–93 (2005).
   PubMed Web of Science ®Google Scholar
• Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology33(7), 1477–1502 (2008).
   PubMed Web of Science ®Google Scholar
• Veiel HO. A preliminary profile of neuropsychological deficits associated with major depression. J. Clin. Exp. Neuropsychol.19(4), 587–603 (1997).
   PubMed Web of Science ®Google Scholar
• Coull JT. Neural correlates of attention and arousal: insights from electrophysiology, functional neuroimaging and psychopharmacology. Prog. Neurobiol.55(4), 343–361 (1998).
   PubMed Web of Science ®Google Scholar
• Elliott R. Executive functions and their disorders. Br. Med. Bull.65, 49–59 (2003).
   PubMed Web of Science ®Google Scholar
• Lezak M. Neuropsychological Assessment. Oxford University Press, NY, USA (1983).
   Google Scholar
• Gohier B, Ferracci L, Surguladze SA et al. Cognitive inhibition and working memory in unipolar depression. J. Affect. Disord.116(1–2), 100–105 (2009).
   PubMed Web of Science ®Google Scholar
• Rose EJ, Ebmeier KP. Pattern of impaired working memory during major depression. J. Affect. Disord.90(2–3), 149–161 (2006).
   PubMed Web of Science ®Google Scholar
• Fava M, Graves LM, Benazzi F et al. A cross-sectional study of the prevalence of cognitive and physical symptoms during long-term antidepressant treatment. J. Clin. Psychiatry67(11), 1754–1759 (2006).
   PubMed Web of Science ®Google Scholar
• Bornstein RA, Baker GB, Douglass AB. Depression and memory in major depressive disorder. J. Neuropsychiatry Clin. Neurosci.3(1), 78–80 (1991).
   PubMedGoogle Scholar
• Landro NI, Stiles TC, Sletvold H. Neuropsychological function in nonpsychotic unipolar major depression. Neuropsychiatry Neuropsychol. Behav. Neurol.14(4), 233–240 (2001).
   PubMedGoogle Scholar
• Williams RA, Hagerty BM, Cimprich B et al. Changes in directed attention and short-term memory in depression. J. Psychiatr. Res.34(3), 227–238 (2000).
   PubMed Web of Science ®Google Scholar
• Zakzanis KK, Leach L, Kaplan E. On the nature and pattern of neurocognitive function in major depressive disorder. Neuropsychiatry Neuropsychol. Behav. Neurol.11(3), 111–119 (1998).
   PubMedGoogle Scholar
• Caine ED, Yerevanian BI, Bamford KA. Cognitive function and the dexamethasone suppression test in depression. Am. J. Psychiatry141(1), 116–118 (1984).
   PubMedGoogle Scholar
• George MS, Ketter TA, Parekh PI et al. Blunted left cingulate activation in mood disorder subjects during a response interference task (the Stroop). J. Neuropsychiatry Clin. Neurosci.9(1), 55–63 (1997).
   PubMed Web of Science ®Google Scholar
• Mahurin RK, Velligan DI, Hazleton B et al. Trail making test errors and executive function in schizophrenia and depression. Clin. Neuropsychol.20(2), 271–288 (2006).
   PubMed Web of Science ®Google Scholar
• Martin DJ, Oren Z, Boone K. Major depressives’ and dysthmics’ performance on the Wisconsin Card Sorting Test. J. Clin. Psychol.47(5), 684–690 (1991).
   PubMed Web of Science ®Google Scholar
• Stordal KI, Lundervold AJ, Egeland J et al. Impairment across executive functions in recurrent major depression. Nord. J. Psychiatry58(1), 41–47 (2004).
   PubMed Web of Science ®Google Scholar
• Trichard C, Martinot JL, Alagille M et al. Time course of prefrontal lobe dysfunction in severely depressed in-patients: a longitudinal neuropsychological study. Psychol. Med.25(1), 79–85 (1995).
   PubMed Web of Science ®Google Scholar
• Naismith SL, Longley WA, Scott EM, Hickie IB. Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study. BMC Psychiatry7, 32 (2007).
   PubMed Web of Science ®Google Scholar
• Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Res.145(1), 39–48 (2006).
   PubMed Web of Science ®Google Scholar
• Paelecke-Habermann Y, Pohl J, Leplow B. Attention and executive functions in remitted major depression patients. J. Affect. Disord.89(1–3), 125–135 (2005).
   PubMed Web of Science ®Google Scholar
• Lavretsky H, Kim MD, Kumar A, Reynolds CF 3rd. Combined treatment with methylphenidate and citalopram for accelerated response in the elderly: an open trial. J. Clin. Psychiatry64(12), 1410–1414 (2003).
   PubMed Web of Science ®Google Scholar
• Lavretsky H, Park S, Siddarth P, Kumar A, Reynolds CF 3rd. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am. J. Geriatr. Psychiatry14(2), 181–185 (2006).
   PubMed Web of Science ®Google Scholar
• DeBattista C, Lembke A, Solvason HB, Ghebremichael R, Poirier J. A prospective trial of modafinil as an adjunctive treatment of major depression. J. Clin. Psychopharmacol.24(1), 87–90 (2004).
   PubMed Web of Science ®Google Scholar
• Holtzheimer PE III, Meeks TW, Kelley ME et al. A double blind, placebo-controlled pilot study of galantamine augmentation of antidepressant treatment in older adults with major depression. Int. J. Geriatr. Psychiatry23(6), 625–631 (2008).
   PubMedGoogle Scholar
• Pelton GH, Harper OL, Tabert MH et al. Randomized double-blind placebo-controlled donepezil augmentation in antidepressant-treated elderly patients with depression and cognitive impairment: a pilot study. Int. J. Geriatr. Psychiatry23(7), 670–676 (2008).
   PubMedGoogle Scholar
• Perlis RH, Fraguas R, Fava M et al. Prevalence and clinical correlates of irritability in major depressive disorder: a preliminary report from the Sequenced Treatment Alternatives to Relieve Depression study. J. Clin. Psychiatry66(2), 159–166 (2005).
   PubMed Web of Science ®Google Scholar
• Overall JE, Goldstein BJ, Brauzer B. Symptomatic volunteers in psychiatric research. J. Psychiatr. Res.9(1), 31–43 (1971).
   PubMed Web of Science ®Google Scholar
• Baker M, Dorzab J, Winokur G, Cadoret RJ. Depressive disease: classification and clinical characteristics. Compr. Psychiatry12(4), 354–365 (1971).
   PubMed Web of Science ®Google Scholar
• Snaith RP, Taylor CM. Irritability: definition, assessment and associated factors. Br. J. Psychiatry147, 127–136 (1985).
   PubMed Web of Science ®Google Scholar
• Akiskal HS, Benazzi F, Perugi G, Rihmer Z. Agitated “unipolar” depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy. J. Affect. Disord.85(3), 245–258 (2005).
   PubMed Web of Science ®Google Scholar
• Simon GE, VonKorff M, Piccinelli M, Fullerton C, Ormel J. An international study of the relation between somatic symptoms and depression. N. Engl. J. Med.341(18), 1329–1335 (1999).
   PubMed Web of Science ®Google Scholar
• Ohayon MM, Schatzberg AF. Using chronic pain to predict depressive morbidity in the general population. Arch. Gen. Psychiatry60(1), 39–47 (2003).
   PubMed Web of Science ®Google Scholar
• Silverstein B. Gender difference in the prevalence of clinical depression: the role played by depression associated with somatic symptoms. Am. J. Psychiatry156(3), 480–482 (1999).
   PubMed Web of Science ®Google Scholar
• Husain MM, Rush AJ, Trivedi MH et al. Pain in depression: STAR*D study findings. J. Psychosom. Res.63(2), 113–122 (2007).
   PubMed Web of Science ®Google Scholar
• Arnold LM, Hudson JI, Keck PE et al. Comorbidity of fibromyalgia and psychiatric disorders. J. Clin. Psychiatry67(8), 1219–1225 (2006).
   PubMed Web of Science ®Google Scholar
• Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurol.8(1), 29 (2008).
   PubMed Web of Science ®Google Scholar
• Arnold LM. Management of fibromyalgia and comorbid psychiatric disorders. J. Clin. Psychiatry69(Suppl. 2), 14–19 (2008).
   PubMed Web of Science ®Google Scholar
• Gilron I. Gabapentin and pregabalin for chronic neuropathic and early postsurgical pain: current evidence and future directions. Curr. Opin. Anaesthesiol.20(5), 456–472 (2007).
   PubMed Web of Science ®Google Scholar
• Rush AJ. STAR*D: what have we learned? Am. J. Psychiatry164(2), 201–204 (2007).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Daly EJ. Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice. Drug Alcohol Depend.88(Suppl. 2), S61–S71 (2007).
   PubMed Web of Science ®Google Scholar
• Segal Z, Vincent P, Levitt A. Efficacy of combined, sequential and crossover psychotherapy and pharmacotherapy in improving outcomes in depression. J. Psychiatry Neurosci.27(4), 281–290 (2002).
   PubMedGoogle Scholar
• Trivedi MH, Kurian BT, Grannemann BD. Clinical predictors in major depressive disorder. Prim. Psychiatry14(6), 47–53 (2007).
   Google Scholar
• Pandi-Perumal SR, Trakht I, Srinivasan V et al. The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. World J. Biol. Psychiatry1–13 (2008).
   Google Scholar
• Anderson AD, Oquendo MA, Parsey RV et al. Regional brain responses to serotonin in major depressive disorder. J. Affect. Disord.82(3), 411–417 (2004).
   PubMed Web of Science ®Google Scholar
• Lekman M, Laje G, Charney D et al. The FKBP5-gene in depression and treatment response – an association study in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Cohort. Biol. Psychiatry63(12), 1103–1110 (2008).
   PubMed Web of Science ®Google Scholar
• Lin E, Chen PS. Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics9(7), 935–946 (2008).
   PubMed Web of Science ®Google Scholar
• Paddock S, Laje G, Charney D et al. Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am. J. Psychiatry164(8), 1181–1188 (2007).
   PubMed Web of Science ®Google Scholar
• Perlis RH, Moorjani P, Fagerness J et al. Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study. Neuropsychopharmacology33, 2810–2819 (2008).
   PubMed Web of Science ®Google Scholar